NO168629C - Fremgangsmaate for fremstilling av oralt administrerbare, antidiabetisk virkende preparater - Google Patents

Fremgangsmaate for fremstilling av oralt administrerbare, antidiabetisk virkende preparater

Info

Publication number
NO168629C
NO168629C NO842291A NO842291A NO168629C NO 168629 C NO168629 C NO 168629C NO 842291 A NO842291 A NO 842291A NO 842291 A NO842291 A NO 842291A NO 168629 C NO168629 C NO 168629C
Authority
NO
Norway
Prior art keywords
active substance
compositions
procedure
preparation
activity
Prior art date
Application number
NO842291A
Other languages
English (en)
Norwegian (no)
Other versions
NO168629B (no
NO842291L (no
Inventor
Rolf Brickl
Gottfried Schepky
Eckhard Rupprecht
Andreas Greischel
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO842291L publication Critical patent/NO842291L/no
Publication of NO168629B publication Critical patent/NO168629B/no
Publication of NO168629C publication Critical patent/NO168629C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO842291A 1983-06-08 1984-06-07 Fremgangsmaate for fremstilling av oralt administrerbare, antidiabetisk virkende preparater NO168629C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833320583 DE3320583A1 (de) 1983-06-08 1983-06-08 Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
NO842291L NO842291L (no) 1984-12-10
NO168629B NO168629B (no) 1991-12-09
NO168629C true NO168629C (no) 1992-03-18

Family

ID=6200886

Family Applications (1)

Application Number Title Priority Date Filing Date
NO842291A NO168629C (no) 1983-06-08 1984-06-07 Fremgangsmaate for fremstilling av oralt administrerbare, antidiabetisk virkende preparater

Country Status (24)

Country Link
US (2) US4708868A (pt)
EP (1) EP0128482B1 (pt)
JP (1) JPS6075435A (pt)
KR (1) KR910004572B1 (pt)
AT (1) ATE49886T1 (pt)
AU (1) AU562803B2 (pt)
CA (1) CA1228300A (pt)
DD (1) DD223360A5 (pt)
DE (2) DE3320583A1 (pt)
DK (1) DK162018C (pt)
ES (1) ES8601697A1 (pt)
FI (1) FI85218C (pt)
GB (1) GB2142235B (pt)
GR (1) GR82363B (pt)
HK (1) HK72287A (pt)
HU (1) HU192407B (pt)
IE (1) IE57792B1 (pt)
IL (1) IL72033A (pt)
MY (1) MY100764A (pt)
NO (1) NO168629C (pt)
NZ (1) NZ208416A (pt)
PT (1) PT78711B (pt)
SG (1) SG48087G (pt)
ZA (1) ZA844295B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5312924A (en) 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
FR2577437A1 (fr) * 1985-02-21 1986-08-22 Corbiere Jerome Nouveau procede de solubilisation des composes chimiques et les preparations aqueuses ainsi obtenues
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DE3927882A1 (de) * 1989-08-23 1991-02-28 Bauer Kurt Heinz Hochwirksame, schnell resorbierbare zubereitungsformen von glibenclamid, verfahren zu ihrer herstellung und ihre verwendung
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
DE69227240T2 (de) * 1991-01-16 1999-04-08 Fmc Corp., Philadelphia, Pa. Träger für wirkstoffe und damit hergestellte feste darreichungsformen
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
ATE184279T1 (de) * 1991-06-21 1999-09-15 Boehringer Ingelheim Pharma Verwendung von (s)(+)-2-äthoxy-4-(n-(1-(2- piperidino-phenyl)-3-methyl-1- butyl>aminocarbonylmethyl>-benzoesäure zur herstellung eines langzeitantidiabetikums
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US6004958A (en) * 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
US7071298B2 (en) * 1997-02-05 2006-07-04 Fox Chase Cancer Center Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
PT1666026E (pt) 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7166301B1 (en) * 1999-05-21 2007-01-23 Kissei Pharmaceutical Co., Ltd. Immediate release medicinal compositions for oral use
ES2295379T3 (es) 2001-06-29 2008-04-16 Eurand Pharmaceuticals Ltd. Procedimiento de activacion termodinamica de medicamentos insolubles en agua cargados en polimeros reticulados.
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20050019399A1 (en) * 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
CN1729005A (zh) * 2002-11-15 2006-02-01 兰贝克赛实验室有限公司 含双胍-磺酰脲类组合的药物剂型
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE399538T1 (de) * 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
EP1610767B1 (en) * 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20100029721A1 (en) * 2006-09-29 2010-02-04 Novo Nordisk A/S Pharmaceutical Formulation Comprising Metformin and Repaglinide
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2228066A1 (en) * 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
PL3412302T3 (pl) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Zmodyfikowane polipeptydy fgf-21 i ich zastosowania
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN115671203B (zh) * 2022-11-24 2023-10-27 广州中医药大学科技产业园有限公司 一种用于降糖降脂的中药复方提取物及其提取方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668215A (en) * 1967-11-25 1972-06-06 Bayer Ag Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
NL138933B (nl) * 1969-03-26 1973-05-15 Erba Carlo Spa Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking.
US3708486A (en) * 1969-04-17 1973-01-02 Boehringer Sohn Ingelheim 2-(p-(n'-cycloalkyl-carbamido-n-sulfonyl)-phenethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4,4-dimethyl-isoquinolines and alkali metal salts thereof
NL7314765A (pt) * 1972-10-31 1974-05-02
DE2657382A1 (de) * 1976-12-17 1978-06-29 Thera Ges Fuer Patente Orales antidiabetikmittel
JPS6026093B2 (ja) * 1978-03-14 1985-06-21 住友製薬株式会社 ゲフアルナート含有固型製剤の製造方法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
ATE22530T1 (de) * 1980-07-29 1986-10-15 Sanofi Sa Durch saeure stabilisierte mischungen von thienopyridinderivaten und verfahren zum verhindern der zersetzung solcher verbindungen.
WO1982000822A1 (en) * 1980-08-29 1982-03-18 Eistetter K Substituted oxiranecarboxylic acids,their preparation and their use as medicaments
DE3100535A1 (de) * 1981-01-10 1982-08-12 Dr. Karl Thomae Gmbh, 7950 Biberach "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3225188A1 (de) * 1982-07-06 1984-01-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
JPS6075435A (ja) 1985-04-27
GR82363B (pt) 1984-12-13
HU192407B (en) 1987-06-29
IE841422L (en) 1984-12-08
GB2142235A (en) 1985-01-16
GB8414528D0 (en) 1984-07-11
FI85218C (fi) 1992-03-25
IL72033A (en) 1987-08-31
EP0128482A2 (de) 1984-12-19
FI85218B (fi) 1991-12-13
FI842295A (fi) 1984-12-09
PT78711A (de) 1984-07-01
PT78711B (de) 1986-10-21
ZA844295B (en) 1986-02-26
KR910004572B1 (ko) 1991-07-06
ES533207A0 (es) 1985-11-16
NO168629B (no) 1991-12-09
MY100764A (en) 1991-02-15
FI842295A0 (fi) 1984-06-07
CA1228300A (en) 1987-10-20
DE3320583A1 (de) 1984-12-13
US4708868A (en) 1987-11-24
NO842291L (no) 1984-12-10
EP0128482B1 (de) 1990-01-31
AU562803B2 (en) 1987-06-18
SG48087G (en) 1987-08-28
JPH0548206B2 (pt) 1993-07-20
KR850000241A (ko) 1985-02-26
IL72033A0 (en) 1984-10-31
DK280884D0 (da) 1984-06-07
ATE49886T1 (de) 1990-02-15
IE57792B1 (en) 1993-04-07
US4873080A (en) 1989-10-10
DK162018B (da) 1991-09-09
DK280884A (da) 1984-12-09
NZ208416A (en) 1987-06-30
DK162018C (da) 1992-02-10
HUT34349A (en) 1985-03-28
AU2924184A (en) 1984-12-13
DE3481170D1 (de) 1990-03-08
GB2142235B (en) 1987-04-08
DD223360A5 (de) 1985-06-12
EP0128482A3 (en) 1986-06-25
ES8601697A1 (es) 1985-11-16
HK72287A (en) 1987-10-16

Similar Documents

Publication Publication Date Title
NO168629C (no) Fremgangsmaate for fremstilling av oralt administrerbare, antidiabetisk virkende preparater
NO842290L (no) Fremgangsmaate for fremstilling av preparater inneholdende oralt antidiabetisk aktive stoffer